Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting anticomplement agents.

R A Smith1

  • 1Adprotech Ltd, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, UK. R.A.Smith@adpro.co.uk

Biochemical Society Transactions
|November 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix.

Archives of biochemistry and biophysics·1995
Same author

The current status of the Papanicolaou smear.

CA: a cancer journal for clinicians·1995
Same author

Screening women aged 40-49 years: where are we today?

Journal of the National Cancer Institute·1995
Same author

Continuous thermodilution cardiac output: agreement with Fick and bolus thermodilution methods.

Journal of cardiothoracic and vascular anesthesia·1995
Same author

Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS.

Journal of the neurological sciences·1995
Same author

Activation of complement by DMSO and ethanol and its inhibition by soluble complement receptor type 1.

Biochemical Society transactions·1995
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

An innovative addressive drug delivery method concentrates agents in blood vessels and at disease sites. This approach, using modified complement receptor-1 (APT070), shows potent anti-inflammatory effects and good tolerability in preclinical and early clinical studies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Traditional biological targeting focuses on direct molecule-to-target interaction in vivo.
  • An addressive approach, concentrating agents in vasculature and disease sites, may enhance therapeutic drug delivery.
  • This strategy is particularly relevant for delivering therapeutic quantities of certain drugs.

Purpose of the Study:

  • To develop and evaluate an addressive drug delivery system for enhanced therapeutic efficacy.
  • To investigate the properties of synthetic peptide derivatives with dual addressin units for cell membrane affinity.
  • To assess the anti-inflammatory potential and safety of a modified complement receptor-1 fragment (APT070).

Main Methods:

  • Synthetic peptide derivatives were engineered with addressin units targeting membrane interiors and phospholipid headgroups.

Related Experiment Videos

  • Modified agents were tested in cell-based antihaemolytic assays to determine potency and membrane binding.
  • Co-localization studies were performed using lipid rafts and glycosylphosphatidylinositol-anchored proteins.
  • APT070 was evaluated in animal models for anti-inflammatory activity and in human subjects for safety.

    • Main Results:

    • The modified peptide derivatives exhibited enhanced affinity for cell membranes, particularly areas with translocated acidic phospholipids.
    • Significant increases in potency were observed in antihaemolytic assays, correlated with membrane binding.
    • Modified agents were found to co-localize with specific proteins within lipid rafts on cell membranes.
    • APT070 demonstrated significant anti-inflammatory activity in animal models and was well-tolerated in human subjects.

    Conclusions:

    • The addressive targeting strategy effectively enhances the potency and localization of therapeutic agents.
    • Modified complement receptor-1 fragment (APT070) is a promising anti-inflammatory agent with potential for treating conditions like rheumatoid arthritis.
    • APT070's favorable safety profile supports further investigation for localized complement inhibition therapies.